Effects of atorvastatin on porcine aqueous humour outflow and trabecular meshwork cells

Cong,Lin; Fu,Shuhao; Zhang,Jinling; Zhao,Jin; Zhang,Yuyan

doi:10.3892/etm.2017.5353

Effects of atorvastatin on porcine aqueous humour outflow and trabecular meshwork cells

Authors:
- Lin Cong
- Shuhao Fu
- Jinling Zhang
- Jin Zhao
- Yuyan Zhang
View Affiliations

Affiliations: Department of Ophthalmology, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China
Published online on: October 23, 2017 https://doi.org/10.3892/etm.2017.5353
Pages: 210-216
Copyright: © Cong et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Primary open-angle glaucoma (POAG) with complex pathogenesis is one of the many major causes of blindness. It is widely accepted that the major cause of POAG is the dysregulation of the trabecular meshwork (TM), which regulates the resistance to aqueous humour outflow. Intraocular pressure is elevated with increasing outflow resistance in the conventional pathway, which consists of the TM and Schlemm's canal. The TM is a filter made up of extracellular matrix (e.g., collagens), most of which is organized into a network of beams covered by endothelial‑like trabecular cells. Currently, lack of effective anti‑glaucoma drugs acting on TM to normalize trabecular outflow represents a bottleneck for POAG therapy. Atorvastatin, a lipid‑lowering drug, has been proven to be of benefit for POAG. The present study aimed to investigate the possible mechanisms of action of atorvastatin on the TM by using a porcine aqueous humour outflow model in vivo and TM cells in vitro. Perfusion of enucleated porcine eyes with atorvastatin (50‑200 µM) for 2 h increased aqueous humour outflow (P<0.05, n=6), possibly via regulating the morphology of TM cells and the distribution of the cytoskeleton. Atorvastatin decreased adhesion molecules at the mRNA and protein level. No cytotoxicity of atorvastatin on TM cells was observed at concentrations of <100 µM. The atorvastatin‑induced effects mentioned above were reversible after removal of the compound only if the atorvastatin concentration was <100 µM. The present study demonstrated that atorvastatin efficaciously elevated aqueous humour outflow, possibly due to affecting TM‑cell morphology, cytoskeleton and cell junctions. Statins may be potential therapeutic agents for lowering intraocular pressure in POAG.

View Figures

View References

1	Overby DR, Stamer WD and Johnson M: The changing paradigm of outflow resistance generation: Towards synergistic models of the JCT and inner wall endothelium. Exp Eye Res. 88:656–670. 2009. View Article : Google Scholar : PubMed/NCBI
2	Fuchshofer R and Tamm ER: Modulation of extracellular matrix turnover in the trabecular meshwork. Exp Eye Res. 88:683–688. 2009. View Article : Google Scholar : PubMed/NCBI
3	Grant WM: Experimental aqueous perfusion in enucleated human eyes. Arch Ophthalmol. 69:783–801. 1963. View Article : Google Scholar : PubMed/NCBI
4	Picht G, Welge-Luessen U, Grehn F and Lütjen-Drecoll E: Transforming growth factor beta 2 levels in the aqueous humor in different types of glaucoma and the relation to filtering bleb development. Graefes Arch Clin Exp Ophthalmol. 239:199–207. 2001. View Article : Google Scholar : PubMed/NCBI
5	Johnson M: What controls aqueous humour outflow resistance? Exp Eye Res. 82:1–557. 2006. View Article : Google Scholar
6	Tamm ER and Fuchshofer R: What increases outflow resistance in primary open-angle glaucoma? Surv Ophthalmol. 52(Suppl 2): S101–S104. 2007. View Article : Google Scholar : PubMed/NCBI
7	Ethier CR, Read AT and Chan DW: Effects of latrunculin-B on outflow facility and trabecular meshwork structure in human eyes. Invest Ophthalmol Vis Sci. 47:1991–1998. 2006. View Article : Google Scholar : PubMed/NCBI
8	Bahler CK, Hann CR, Fautsch MP and Johnson DH: Pharmacologic disruption of Schlemm's canal cells and outflow facility in anterior segments of human eyes. Invest Ophthalmol Vis Sci. 45:2246–2254. 2004. View Article : Google Scholar : PubMed/NCBI
9	Hu Y, Gabelt BT and Kaufman PL: Monkey organ-cultured anterior segments: Technique and response to H-7. Exp Eye Res. 82:1100–1108. 2006. View Article : Google Scholar : PubMed/NCBI
10	Tian B, Gabelt BT, Geiger B and Kaufman PL: The role of the actomyosin system in regulating trabecular fluid outflow. Exp Eye Res. 88:713–717. 2009. View Article : Google Scholar : PubMed/NCBI
11	Bornstein P: Matricellular proteins: An overview. J Cell Commun Signal. 3:163–165. 2009. View Article : Google Scholar : PubMed/NCBI
12	Haddadin RI, Oh DJ, Kang MH, Filippopoulos T, Gupta M, Hart L, Sage EH and Rhee DJ: SPARC-null mice exhibit lower intraocular pressures. Invest Ophthalmol Vis Sci. 50:3771–3777. 2009. View Article : Google Scholar : PubMed/NCBI
13	Clark AF and Pang IH: Advances in glaucoma therapeutics. Expert Opin Emerg Drugs. 7:141–163. 2002. View Article : Google Scholar : PubMed/NCBI
14	Cai S, Liu X, Glasser A, Volberg T, Filla M, Geiger B, Polansky JR and Kaufman PL: Effect of latrunculin-A on morphology and actin-associated adhesions of cultured human trabecular meshwork cells. Mol Vis. 6:132–143. 2000.PubMed/NCBI
15	Rao PV, Deng PF, Kumar J and Epstein DL: Modulation of aqueous humor outflow facility by the Rho kinase-specific inhibitor Y-27632. Invest Ophthalmol Vis Sci. 42:1029–1037. 2001.PubMed/NCBI
16	Gabelt BT, Hu Y, Vittitow JL, Rasmussen CR, Grosheva I, Bershadsky AD, Geiger B, Borrás T and Kaufman PL: Caldesmon transgene expression disrupts focal adhesions in HTM cells and increases outflow facility in organ-cultured human and monkey anterior segments. Exp Eye Res. 82:935–944. 2006. View Article : Google Scholar : PubMed/NCBI
17	Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W and Gotto AM Jr: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air force/texas coronary atherosclerosis prevention study. JAMA. 279:1615–1622. 1998. View Article : Google Scholar : PubMed/NCBI
18	Endo A: The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res. 33:1569–1582. 1992.PubMed/NCBI
19	Vaughan CJ and Delanty N: Neuroprotective properties of statins in cerebral ischemia and stroke. Stroke. 30:1969–1973. 1999. View Article : Google Scholar : PubMed/NCBI
20	Zacco A, Togo J, Spence K, Ellis A, Lloyd D, Furlong S and Piser T: 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors protect cortical neurons from excitotoxicity. J Neurosci. 23:11104–11111. 2003.PubMed/NCBI
21	Schmeer C, Kretz A and Isenmann S: Statin-mediated protective effects in the central nervous system: General mechanisms and putative role of stress proteins. Restor Neurol Neurosci. 24:79–95. 2006.PubMed/NCBI
22	Yin H, Gui Y and Zheng XL: 2-methoxyestradiol inhibits atorvastatin-induced rounding of human vascular smooth muscle cells. J Cell Physiol. 222:556–564. 2010.PubMed/NCBI
23	Song J, Deng PF, Stinnett SS, Epstein DL and Rao PV: Effects of cholesterol-lowering statins on the aqueous humor outflow pathway. Invest Ophthalmol Vis Sci. 46:2424–2432. 2005. View Article : Google Scholar : PubMed/NCBI
24	Burridge K and Wennerberg K: Rho and Rac take center stage. Cell. 116:167–179. 2004. View Article : Google Scholar : PubMed/NCBI
25	Etienne-Manneville S and Hall A: Rho GTPases in cell biology. Nature. 420:629–635. 2002. View Article : Google Scholar : PubMed/NCBI
26	Kaibuchi K, Kuroda S and Amano M: Regulation of the cytoskeleton and cell adhesion by the Rho family GTPases in mammalian cells. Annu Rev Biochem. 68:459–486. 1999. View Article : Google Scholar : PubMed/NCBI
27	Somlyo AP and Somlyo AV: Signal transduction through the RhoA/Rho-kinase pathway in smooth muscle. J Muscle Res Cell Motil. 25:613–615. 2004.PubMed/NCBI
28	Wang J, Liu X and Zhong Y: Rho/Rho-associated kinase pathway in glaucoma (Review). Int J Oncol. 43:1357–1367. 2013. View Article : Google Scholar : PubMed/NCBI
29	Stein JD, Newman-Casey PA, Talwar N, Nan B, Richards JE and Musch DC: The relationship between statin use and open-angle glaucoma. Ophthalmology. 119:2074–2081. 2012. View Article : Google Scholar : PubMed/NCBI
30	De Castro DK, Punjabi OS, Bostrom AG, Stamper RL, Lietman TM, Ray K and Lin SC: Effect of statin drugs and aspirin on progression in open-angle glaucoma suspects using confocal scanning laser ophthalmoscopy. Clin Exp Ophthalmol. 35:506–513. 2007. View Article : Google Scholar : PubMed/NCBI
31	Openkova YY, Korobeiynikova EN, Rykin VS and Vinkova GA: The analysis of status of biochemical indicators in blood serum and lacrimal fluid in patients with primary open-angle glaucoma. Klin Lab Diagn. 8–11. 2013.(In Russian). PubMed/NCBI
32	DiNicolantonio JJ, Lavie CJ, Serebruany VL and O'Keefe JH: Statin wars: The heavyweight match-atorvastatin versus rosuvastatin for the treatment of atherosclerosis, heart failure, and chronic kidney disease. Postgrad Med. 125:7–16. 2013. View Article : Google Scholar : PubMed/NCBI
33	Stoekenbroek RM, Boekholdt SM, Fayyad R, Laskey R, Tikkanen MJ, Pedersen TR and Hovingh GK; Incremental Decrease in End Points Through Aggressive Lipid Lowering Study Group, : High-dose atorvastatin is superior to moderate-dose simvastatin in preventing peripheral arterial disease. Heart. 101:356–362. 2015. View Article : Google Scholar : PubMed/NCBI
34	Sillesen H, Amarenco P, Hennerici MG, Callahan A, Goldstein LB, Zivin J, Messig M and Welch KM: Stroke Prevention by Aggressive Reduction in Cholesterol Levels Investigators: Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: A secondary analysis of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) trial. Stroke. 39:3297–3302. 2008. View Article : Google Scholar : PubMed/NCBI
35	Zhang Y, Toris CB, Liu Y, Ye W and Gong H: Morphological and hydrodynamic correlates in monkey eyes with laser induced glaucoma. Exp Eye Res. 89:748–756. 2009. View Article : Google Scholar : PubMed/NCBI
36	Polansky JR, Weinreb RN, Baxter JD and Alvarado J: Human trabecular cells. I. Establishment in tissue culture and growth characteristics. Invest Ophthalmol Vis Sci. 18:1043–1049. 1979.PubMed/NCBI
37	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
38	Barany EH and Gassmann HB: The effect of death on outflow resistance in normal and sympathectomized rabbit eyes. Invest Ophthalmol. 4:206–210. 1965.PubMed/NCBI
39	Erickson-Lamy K, Schroeder AM, Bassett-Chu S and Epstein DL: Absence of time-dependent facility increase (“washout”) in the perfused enucleated human eye. Invest Ophthalmol Vis Sci. 31:2384–2388. 1990.PubMed/NCBI
40	Vaajanen A, Vapaatalo H and Oksala O: A modified in vitro method for aqueous humor outflow studies in enucleated porcine eyes. J Ocul Pharmacol Ther. 23:124–131. 2007. View Article : Google Scholar : PubMed/NCBI
41	Rao PV, Deng P, Sasaki Y and Epstein DL: Regulation of myosin light chain phosphorylation in the trabecular meshwork: Role in aqueous humour outflow facility. Exp Eye Res. 80:197–206. 2005. View Article : Google Scholar : PubMed/NCBI
42	Khurana RN, Deng PF, Epstein DL and Rao P Vasantha: The role of protein kinase C in modulation of aqueous humor outflow facility. Exp Eye Res. 76:39–47. 2003. View Article : Google Scholar : PubMed/NCBI
43	Epstein DL, Roberts BC and Skinner LL: Nonsulfhydryl-reactive phenoxyacetic acids increase aqueous humor outflow facility. Invest Ophthalmol Vis Sci. 38:1526–1534. 1997.PubMed/NCBI
44	Pokrovskaya O, Wallace D and O'Brien C: The emerging role of statins in glaucoma pathological mechanisms and therapeutics. Open J Ophthalmol. 4:124–138. 2014. View Article : Google Scholar